Finally, another recent work showed that NSCLC patients with KRAS/STK11 co-mutation, treated with ICIs as second- or third-line of therapy, experienced a worse PFS and OS compared with those with STK11 mutation alone (median PFS, 2.4 months vs. 5.1 months, p = 0.048; median OS, 7.1 months vs. 16.1 months, p < 0.001) [159]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.